Study Summary
This study is evaluating whether an experimental treatment called GLPG5101 helps to treat non-Hodgkin lymphoma (NHL) and if it is safe to use. This study will be carried out in 2 phases: * The first phase is to see which doses of GLPG5101 work best with the least number of side effects. * In the second phase, participants will receive the selected dose(s) based on the results in the first phase.
Interested in this trial?
Submit an InquiryInterventions
GLPG5101GENETIC
Autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| Tufts Medical Center | Boston | Massachusetts | United States |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | United States |
| Dana-Farber Cancer Institute | Boston | Massachusetts | United States |
| Antwerp University Hospital | Edegem | Belgium | |
| UZ Leuven | Leuven | Belgium | |
| CHU De Liège | Liège | Belgium | |
| Cliniques Universitaires Saint-Luc | Woluwe-Saint-Lambert | Belgium | |
| Academisch Medisch Centrum | Amsterdam | Netherlands | |
| Leiden University Medical Center | Leiden | Netherlands | |
| Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | Rotterdam | Netherlands |